Escitalopram Oxalate Ip

Key specifications outlined in the IP monograph for Escitalopram Oxalate typically include:

Identification: Methods to confirm the presence and purity of Escitalopram Oxalate, ensuring it meets defined standards without contamination from other substances.

Assay: Quantitative determination of the potency of Escitalopram Oxalate, usually expressed as a percentage of the labeled amount, ensuring consistency in therapeutic efficacy.

Related Substances: Limits on impurities and degradation products to maintain purity and safety.

Residual Solvents: Maximum allowable levels of solvents used in manufacturing, ensuring the final product is free from harmful residues.

Loss on Drying: Measurement of moisture content to prevent degradation and ensure stability throughout storage and use.

Heavy Metals: Strict limits on toxic heavy metals such as lead, arsenic, mercury, and cadmium to ensure product safety.

Microbial Limits: Specifications ensuring the absence of harmful microorganisms, maintaining microbiological purity.

Particle Size Distribution: Requirements for particle size uniformity to optimize dissolution and absorption, enhancing bioavailability.

Uniformity of Dosage Units: Criteria ensuring consistent dosage across individual tablets or capsules, crucial for treatment efficacy.

Packaging: Specifications for materials and labeling that preserve the integrity and stability of Escitalopram Oxalate during storage and distribution.